PRTA Prothena Corp Public Ltd Co

Price (delayed)

$22.52

Market cap

$1.21B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.22

Enterprise value

$675.57M

Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapeutics with the potential to change the course of devastating ...

Highlights
The company's gross profit has surged by 63% YoY but it fell by 2.3% QoQ
Prothena's revenue has soared by 63% YoY but it has decreased by 2.3% from the previous quarter
Prothena's debt has soared by 156% YoY and by 6% from the previous quarter
The net income has contracted by 35% YoY and by 17% from the previous quarter

Key stats

What are the main financial stats of PRTA
Market
Shares outstanding
53.77M
Market cap
$1.21B
Enterprise value
$675.57M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.41
Price to sales (P/S)
13.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.57
Earnings
Revenue
$89.25M
EBIT
-$185.14M
EBITDA
-$177.6M
Free cash flow
-$162.33M
Per share
EPS
-$3.22
Free cash flow per share
-$3.02
Book value per share
$9.35
Revenue per share
$1.66
TBVPS
$11.6
Balance sheet
Total assets
$623.19M
Total liabilities
$120.8M
Debt
$12.5M
Equity
$502.4M
Working capital
$522.6M
Liquidity
Debt to equity
0.02
Current ratio
13.08
Quick ratio
12.66
Net debt/EBITDA
3.01
Margins
EBITDA margin
-199%
Gross margin
100%
Net margin
-193.2%
Operating margin
-242.3%
Efficiency
Return on assets
-24.7%
Return on equity
-30.5%
Return on invested capital
-742%
Return on capital employed
-31.9%
Return on sales
-207.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PRTA stock price

How has the Prothena stock price performed over time
Intraday
-3.72%
1 week
5.53%
1 month
7.24%
1 year
-70.37%
YTD
-38.03%
QTD
-9.08%

Financial performance

How have Prothena's revenue and profit performed over time
Revenue
$89.25M
Gross profit
$89.25M
Operating income
-$216.24M
Net income
-$172.4M
Gross margin
100%
Net margin
-193.2%
The company's gross profit has surged by 63% YoY but it fell by 2.3% QoQ
Prothena's revenue has soared by 63% YoY but it has decreased by 2.3% from the previous quarter
Prothena's operating income has decreased by 44% YoY and by 13% QoQ
The net income has contracted by 35% YoY and by 17% from the previous quarter

Growth

What is Prothena's growth rate over time

Valuation

What is Prothena stock price valuation
P/E
N/A
P/B
2.41
P/S
13.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.57
The company's EPS fell by 25% YoY and by 17% QoQ
PRTA's price to book (P/B) is 41% lower than its last 4 quarters average of 4.1 and 37% lower than its 5-year quarterly average of 3.8
The company's equity fell by 17% YoY and by 11% QoQ
PRTA's price to sales (P/S) is 95% lower than its 5-year quarterly average of 295.1 and 54% lower than its last 4 quarters average of 29.3
Prothena's revenue has soared by 63% YoY but it has decreased by 2.3% from the previous quarter

Efficiency

How efficient is Prothena business performance
The ROIC has grown by 43% YoY and by 23% from the previous quarter
Prothena's return on assets has decreased by 26% YoY and by 22% QoQ
The ROE has decreased by 23% from the previous quarter and by 22% YoY
The company's return on sales fell by 18% QoQ but it rose by 17% YoY

Dividends

What is PRTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PRTA.

Financial health

How did Prothena financials performed over time
The total assets has decreased by 16% YoY and by 11% from the previous quarter
PRTA's current ratio is up by 16% since the previous quarter but it is down by 9% year-on-year
Prothena's debt is 98% less than its equity
Prothena's debt has soared by 156% YoY and by 6% from the previous quarter
Prothena's debt to equity has surged by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.